Reason reports back from Rejuvenation Startup Summit 2024
Fight Aging! - 13-May-2024A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials
Join the club for FREE to access the whole archive and other member benefits.
Drug development company focused on the senolytic technology to fight age-related diseases
Oisin Biotechnologies is a platform drug development company focused on creating drugs to combat a variety of age related diseases.
When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function.
Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases.
Visit website: https://www.oisinbio.com/
Details last updated 04-May-2019
Matthew Scholz delivered a keynote on body-wide gene therapy using proteo-lipid vehicles
CSO Oision Biotechnologies, co-founder of Oisin Oncology and Chair in Prostate Cancer Research at the University of Alberta
A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials
Most approaches have their limitations but good progress is being made on several fronts
Investigational therapy on old mice cleared senescent cells up to 70%, extending life by 20%
Comprehensive review of companies' clinical and financial state of play
In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...
Allowing developments on tech that will kill cancer based on their genetics
When some of these succeed in human trials even more money will pile in to fund further advances
Phase 1 clinical trial starting early 2020
R&D phase in SENS repair approach has shown promising results
Researchers commonly determine the presence of senescent cells through the use of the p16ink4a (p...
Study directly targets one of the mechanisms that senescent cells use to avoid apoptosis, Focuse...
It is focused on the twofold path of (a) establishing patient-funded trials of potentially usefu...
Each treatment will target a different type of molecular damage in cells and tissues. 1) Clearan...